Keyword Search
 
2018 | 2017 | 2016 | 2015
Exercise of Warrants
December 22, 2015
Motif Bio plc (AIM:MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announces that the Company will issue 35,925 ordinary shares of 1 penny each ("Option Shares")  in settlement of options that have been exercised.  The options were exercised at a price of US $0.20 per ordinary share for total consideration of US $7,185.Admission to trading on AIM ("Admission") of the Option Shares, which will rank pari passu with the existing Ordin... Read More
Iclaprim Clinical Trial Supplies Manufactured
December 15, 2015
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that clinical trial supplies in the form of sterile ampoules of iclaprim have been manufactured. Following Quality Assurance release, these supplies will be shipped to clinical trial sites. These activities enable Motif to remain on target to complete the two, previously announced Phase III ABSSSI trials in H2 2017.Graham Lumsden, CEO, stated: "This is a major mil... Read More
Motif selected to present at Biotech Showcase, San Francisco, January 2016
December 7, 2015
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has been selected to present at the Biotech Showcase 2016, San Francisco, on:Monday, January 11, 2016 at 14:00 PSTTrack: D – Powell (3rd Floor)Biotech Showcase, which runs alongside the largest healthcare investor event of the year – the JP Morgan Annual Healthcare Conference – is an investor and partnering conference dedicated to providing privat... Read More
Receipt of FDA Concurrence with Optimized Dose for Iclaprim Phase III Clinical Trials
November 24, 2015
Motif Bio plc (AIM:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that it has received written concurrence from the United States Food and Drug Administration ("FDA") for an optimized fixed dose of iclaprim of 80mg for all patients except those with moderate hepatic impairment, regardless of body weight, in the Company's proposed Phase III clinical trials for the treatment of acute bacterial skin and skin structure infection... Read More
European Agreement for Iclaprim Phase III Clinical Development Programme
November 11, 2015
Motif Bio plc (AIM:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that it has received written advice from a Scientific Advice Meeting with the Medicines Evaluation Board (MEB) in Utrecht, The Netherlands, held on 16 September 2015, in relation to the Phase III Clinical Development Programme for iclaprim.The MEB's advice confirms that two Phase III clinical trials plus microbiological data derived from the planned surveillance st... Read More
Selected to Present at BIO-Europe 2015
October 27, 2015
Motif Bio plc (AIM:MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has been selected to present at BIO-Europe, a leading European pharmaceutical-biotechnology conference. The CEO of Motif, Graham Lumsden, will present.Presentation dates:The BIO-Europe 2015 conference on November 2 through November 4, 2015 at the International Congress Center (ICM) in Munich, Germany. Motif will be presenting at 16:45 CET on Novembe... Read More
Exercise of Options
October 21, 2015
Motif Bio plc (AIM:MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announces that the Company will issue 25,147 ordinary shares of 1 penny each ("Option Shares")  in settlement of options that have been exercised by a former employee.  The options were exercised at a price of US $0.695908 per ordinary share for total consideration of US $17,500.Admission to trading on AIM ("Admission") of the Option Shares, which will rank pari pas... Read More
Contract Signed With Leading CRO to Conduct Iclaprim Phase III Clinical Trials
October 16, 2015
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced the signing of a clinical trials agreement with Covance, a leading global Contract Research Organisation (CRO), and a wholly owned subsidiary of Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH).  The trials under the agreement are for iclaprim, a targeted spectrum antibiotic designed to be effective against multi-drug-resistant bacteria, incl... Read More
Announces Results of Two Posters on Iclaprim at ID Week 2015
October 13, 2015
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced results of two iclaprim clinical studies that were presented at the Infectious Disease Week 2015 (ID Week) conference in San Diego, California on 9 October, 2015. Iclaprim is a novel antibiotic, targeting the bacterial dihydrofolate reductase enzyme, which is currently starting two Phase III clinical trials to treat acute bacterial skin and skin structure infectio... Read More
Exercise of Options
October 12, 2015
Motif Bio plc (AIM:MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announces that the Company will issue 53,887 ordinary shares of 1 penny each ("Option Shares")  in settlement of options that have been exercised by a former director. The options were exercised at a price of US $0.13918 per ordinary share for total consideration of US $7,500.Admission to trading on AIM ("Admission") of the Option Shares, which will rank pari passu with ... Read More
Directors Dealings
October 5, 2015
Motif (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics was notified, on 2 October 2015 that Dr. John Stakes, Non Executive Director of Motif, purchased 100,000 ordinary shares in the Company at 60 pence per ordinary share on 2 October 2015. Accordingly, Dr. John Stakes owns 171,850 ordinary shares, representing approximately 0.16 per cent of the Company's issued share capital.Motif Bio plcGraham Lumsden, Chief Executive Officer Robert Berto... Read More
Motif Announces Presentation of Two Posters on Iclaprim at ID Week 2015
September 29, 2015
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that data from two iclaprim clinical studies have been accepted for presentation at the Infectious Disease Week 2015 (ID Week) conference in San Diego, California which runs from the 7th to the 11th of October 2015. Iclaprim is a novel antibiotic, targeting the bacterial dihydrofolate reductase enzyme, currently beginning two Phase III studies to treat acute bacte... Read More
Issue of Shares for Exercised Warrants
September 23, 2015
Motif (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announces that the Company has issued 140,321 new Ordinary Shares in settlement of an exercise of warrants.  The exercise price of the warrants was 20 pence.  The new Ordinary Shares represent 0.13% of the enlarged issued share capital.Admission to trading on AIM of the 140,321 new Ordinary Shares, which rank parri passu with the existing Ordinary Shares, is expected on 2... Read More
FDA Grants Fast Track Designation for Iclaprim
September 3, 2015
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for iclaprim intravenous (IV) to treat Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Hospital Acquired Bacterial Pneumonia (HABP).The FDA's Fast Track programme is designed to aid the development and accelerate the review of new drugs that are inten... Read More
Participation at Upcoming Investor Events
September 2, 2015
Motif (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that management will participate in three upcoming investor events as outlined below.The Rodman & Renshaw Annual Global Investment Conference on September 8 through September 10, 2015 at the St. Regis Hotel in New York. Motif will be presenting at 2:10 pm on September 10 in the Louis XVI A room.BioCentury's 22nd Annual NewsMakers in the Biotech Industry... Read More
Interims Results for the Six months to 30 June 2015
August 27, 2015
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today its maiden interim financial results as an AIM-listed Company. Download the condensed consolidated statement of comprehensive income for the six months ended 30 June 2015Corporate/operational highlights:On 2 April 2015, the Company completed an AIM listing raising £2.8 million at 20 pence per share;The U.S. Food and Drug Administration (FDA) agreed to Phase III tr... Read More
Potent Efficacy of Iclaprim Confirmed in Independent Laboratory Study
August 24, 2015
Motif (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced the topline results of an independent report from microbiology specialists, JMI Laboratories. The report shows that iclaprim is effective in vitro against a range of Gram-positive bacteria, including Staphylococcus aureus, one of the key causes of acute bacterial skin and skin structure infection (ABSSSI) and hospital-acquired bacterial pneumonia (HABP).The recently compl... Read More
Final condition of £22 million placing satisfied with FDA QIDP Designation for iclaprim
July 22, 2015
Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that further to the Company's announcement on Friday 17 July 2015, the US Food & Drug Administration ("FDA") has designated iclaprim, a broad-spectrum antibiotic designed to be effective against multi-drug resistant bacteria, as a Qualified Infectious Diseases Product ("QIDP") for hospital acquired bacterial pneumonia ("HABP"), the final condition of the £22 million... Read More
FDA QIDP Designation for Motif’s Lead Antibiotic Candidate Iclaprim for ABSSSI
July 22, 2015
Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that the U.S. Food & Drug Administration (FDA) has designated iclaprim, a broad-spectrum antibiotic designed to be effective against multi-drug resistant bacteria, as a Qualified Infectious Diseases Product (QIDP) for acute bacterial skin and skin structure infections (ABSSSI).The Company requested QIDP designation for iclaprim for two serious and life threatening i... Read More
Exercise of Options
July 20, 2015
Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company will issued 25,147 ordinary shares of 1 penny each ("Option Shares") in settlement of options that have been exercised by a former employee. The options were exercised at prices of US $0.20877 and $0.69589 per ordinary share for total consideration of US $8,750.Admission to trading on AIM ("Admission") of the Option Shares, which will rank pari pas... Read More
FDA QIDP Designation for Motif’s Lead Antibiotic Candidate Iclaprim for HABP
July 17, 2015
Motif Bio plc. (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that the U.S. Food & Drug Administration (FDA) has designated iclaprim, a broad-spectrum antibiotic designed to be effective against multi-drug resistant bacteria, as a Qualified Infectious Diseases Product (QIDP) for hospital acquired bacterial pneumonia (HABP)The Company requested QIDP designation for Iclaprim for two serious and life threatening infections, HABP... Read More
Motif Bio Appoints Dr. Thomas M. File to its Scientific Advisory Board
July 15, 2015
Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced the appointment of Dr. Thomas M. File to its Scientific Advisory Board. Currently, Dr. File, a renowned expert in infectious diseases, Chairs the Division of Infectious Diseases at Summa Health System, Akron, Ohio, is Professor of Internal Medicine and Master Teacher, and the Chair of the Infectious Disease Section of Northeast Ohio Medical University (NEOMED).&nb... Read More
Result of General Meeting
July 10, 2015
Motif Bio plc, the clinical stage biopharmaceutical company specialising in developing novel antibiotics, is pleased to announce that at the General Meeting held earlier today all resolutions as set out in the Notice of General Meeting annexed to the circular to shareholders dated 23 June 2015 were duly passed. The passing of the resolutions represents the satisfaction of the first of the two conditions to completion of the conditional placing of 44,000,000 ordinary shar... Read More
Exercise of Options
July 10, 2015
Motif Bio plc (AIM:MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company will issued 82,627 ordinary shares of 1 penny each ("Option Shares")  in settlement of options that have been exercised by a former employee.  The options were exercised at a price of US $0.2088 per ordinary share for total consideration of US $17,252.52.Admission to trading on AIM ("Admission") of the Option Shares, which will rank pari p... Read More
Placing to Raise £22 million, Appointment of Nominated Adviser and Joint Broker and Notice of General Meeting
June 23, 2015
Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, is pleased to announce that the Company has today conditionally placed 44,000,000 new ordinary shares, through Zeus Capital and Northland Capital Partners as joint brokers to the Company, at a placing price of 50p per ordinary share with institutional investors to raise £22 million.View the Placement The Placing is conditional, inter alia, upon:(i) Shareholders approving the Reso... Read More
Motif Bio Releases Audited Non-statutory Financial Statements for the Year Ended 31 December 2014
June 9, 2015
Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, reports to the market today the non-statutory financial statements of its wholly-owned subsidiary, Motif BioSciences, Inc. for the year ended 31 December 2014 – a period prior to the completion of the Company's merger, acquisition, and admission to AIM.Since the end of the period covered by these financial statements, Motif Bio plc has completed the Group re-organisation, a neces... Read More
Motif Bio Featured on IG
June 8, 2015
... Read More
Motif partners with Leading Global CRO for Phase III Clinical Trials with Iclaprim
June 1, 2015
Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that its wholly-owned subsidiary, Motif BioSciences Inc., has signed Letters of Intent (LOIs) and interim agreements with a leading global Clinical Research Organisation (CRO). Under the terms of these interim agreements, the CRO will undertake preparations for two Phase III, randomised, double-blind, multicenter clinical trials to evaluate the efficacy and safety... Read More
Motif Receives FDA Meeting Minutes Confirming Iclaprim Phase III Clinical Development Programme
May 28, 2015
Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that it has received the official meeting minutes from the U.S. Food and Drug Administration (FDA) guidance meeting which was held on 14 April 2015. The minutes confirm the FDA's agreement with Motif's Phase III clinical development programme for iclaprim, a broad-spectrum antibiotic designed to be effective against multi-drug resistant bacteria.Iclaprim, a novel ... Read More
Motif Selected to Present at World’s Largest Biotech Event
May 12, 2015
Motif Bio plc, the clinical stage biopharmaceutical company specialising in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria, announced today that the Company has been selected to present at the 2015 BIO International Convention, the leading global event for the Biotechnology sector.BIO International is the world's largest biotech meeting, regularly attracting 15,000 of the world's most powerful biotechn... Read More
Funding Strategy Update
May 7, 2015
The Board of Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today updated investors with its funding strategy following agreement on 14th April 2015 by the U.S. Food and Drug Administration (FDA) with the proposed Phase 3 clinical development programme for the Company's lead product candidate, iclaprim.  The Company anticipates commencing Phase 3 trials in the second half of this year.To fund these trials Motif is contin... Read More
Motif Gains FDA Agreement to Enter Phase 3 Clinical Development with Iclaprim
April 15, 2015
Iclaprim safety and efficacy to be studied in two serious and life-threatening infections.Motif Bio plc (LSE: MTFB), announced today that the U.S. Food and Drug Administration (FDA) has agreed to the proposed Phase 3 clinical development programme for the Company's lead product candidate, iclaprim. The Phase 3 programme is designed to obtain marketing approval for an intravenous formulation of iclaprim in the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital a... Read More
First Day of Dealings: Clinical stage biopharmaceutical company developing new antibiotics admitted to AIM
April 2, 2015
Motif Bio plc, a clinical stage biopharmaceutical company specialising in the development of antibiotics, is pleased to announce that admission and trading of its Ordinary Shares commences today on AIM with the ticker MTFB.KEY POINTS:The Company has a lead antibiotic candidate, iclaprim, in clinical development. The directors anticipate that iclaprim could be ready for commercialisation within approximately 36 months.The Company is seeking to confirm in meetings with the FDA and EMA in the first... Read More
Motif Intending to Seek a Quotation on AIM on March 31
March 18, 2015
... Read More
Motif Bio Announces Intention to Float on AIM
February 2, 2015
Motif Bio Limited to be re-named Motif Bio plc on re-registration as a public listed company ("Motif", the "Company" or the "Group")Intention to Float on AIMClinical stage biopharmaceutical company developing new antibioticsSeeking to raise at least £4 millionMotif Bio plc is seeking to raise at least £4 million through a placing of new ordinary shares (the "Placing") and admission to trading on AIM.Motif is a clinical stage biopharmaceutical company which specialises in developing novel antibio... Read More
Motif Bio Acquires Late Stage Antibiotic and Announces Pre-IPO Financing
January 19, 2015
Amphion Innovations, a developer of medical, life science, and technology businesses, is pleased to announce that Partner Company, Motif BioSciences Inc. ("Motif"), has entered into an agreement to merge with a private company that holds the intellectual property and world-wide rights to a clinical stage antibiotic designed to be effective against MRSA and multi-drug resistant bacteria (the "Acquisition"). Motif plans to start Phase III trials this year in two serious hospital-acquired infection... Read More